Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia

Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia

Abstract The FDA-approved DNA hypomethylating agents (DHAs) like 5-azacytidine (5AC) and decitabine (DAC) demonstrate efficacy in the treatment of hematologic malignancies. Despite previous reports that showed histone acetylation changes upon using these agents, the exact mechanism underpinning thes...

Full description

Bibliographic Details
Main Authors: Hetty E. Carraway, Sridhar A. Malkaram, Yana Cen, Aymen Shatnawi, Jun Fan, Hamdy E. A. Ali, Zakaria Y. Abd Elmageed, Thomm Buttolph, James Denvir, Donald A. Primerano, Tamer E. Fandy
Format: Article
Language:English
Published: Nature Portfolio 2020-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-020-67170-8

Internet

https://doi.org/10.1038/s41598-020-67170-8

Similar Items